These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 18227404

  • 1. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability.
    Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Kobayashi K, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T.
    Hypertension; 2008 Mar; 51(3):734-41. PubMed ID: 18227404
    [Abstract] [Full Text] [Related]

  • 2. Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits.
    Imanishi T, Kuroi A, Ikejima H, Kobayashi K, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T.
    Hypertens Res; 2008 Mar; 31(3):575-84. PubMed ID: 18497479
    [Abstract] [Full Text] [Related]

  • 3. Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits.
    Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Kobayashi K, Shiomi M, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T.
    Hypertens Res; 2008 Jun; 31(6):1199-208. PubMed ID: 18716369
    [Abstract] [Full Text] [Related]

  • 4. Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats.
    Bayorh MA, Mann G, Walton M, Eatman D.
    Clin Exp Hypertens; 2006 Feb; 28(2):121-32. PubMed ID: 16546838
    [Abstract] [Full Text] [Related]

  • 5. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
    Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H, Tanimoto T, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T.
    Hypertension; 2008 Sep; 52(3):563-72. PubMed ID: 18645051
    [Abstract] [Full Text] [Related]

  • 6. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
    Ikejima H, Imanishi T, Tsujioka H, Kuroi A, Kobayashi K, Shiomi M, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T.
    J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
    De Gennaro Colonna V, Rigamonti A, Fioretti S, Bonomo S, Manfredi B, Ferrario P, Bianchi M, Berti F, Muller EE, Rossoni G.
    Eur J Pharmacol; 2005 Jun 15; 516(3):253-9. PubMed ID: 15963975
    [Abstract] [Full Text] [Related]

  • 8. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
    Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J.
    J Am Coll Cardiol; 2003 Nov 05; 42(9):1666-73. PubMed ID: 14607457
    [Abstract] [Full Text] [Related]

  • 9. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.
    Nakhoul F, Khankin E, Yaccob A, Kawachi H, Karram T, Awaad H, Nakhoul N, Hoffman A, Abassi Z.
    Am J Physiol Renal Physiol; 2008 Mar 05; 294(3):F628-37. PubMed ID: 18094029
    [Abstract] [Full Text] [Related]

  • 10. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.
    Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M.
    Circulation; 2004 May 11; 109(18):2213-20. PubMed ID: 15123520
    [Abstract] [Full Text] [Related]

  • 11. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B.
    Clin J Am Soc Nephrol; 2006 Sep 11; 1(5):940-51. PubMed ID: 17699311
    [Abstract] [Full Text] [Related]

  • 12. Enalapril improves impairment of SERCA-derived relaxation and enhancement of tyrosine nitration in diabetic rat aorta.
    Taguchi K, Kobayashi T, Hayashi Y, Matsumoto T, Kamata K.
    Eur J Pharmacol; 2007 Feb 05; 556(1-3):121-8. PubMed ID: 17196960
    [Abstract] [Full Text] [Related]

  • 13. Synergistic interaction between enalapril, L-arginine and tetrahydrobiopterin in smooth muscle cell apoptosis and aortic remodeling induction in SHR.
    Der Sarkissian S, Marchand EL, Duguay D, deBlois D.
    Br J Pharmacol; 2004 Jul 05; 142(5):912-8. PubMed ID: 15197102
    [Abstract] [Full Text] [Related]

  • 14. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction.
    Schäfer A, Fraccarollo D, Hildemann SK, Tas P, Ertl G, Bauersachs J.
    Cardiovasc Res; 2003 Jun 01; 58(3):655-62. PubMed ID: 12798439
    [Abstract] [Full Text] [Related]

  • 15. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
    Kang YS, Ko GJ, Lee MH, Song HK, Han SY, Han KH, Kim HK, Han JY, Cha DR.
    Nephrol Dial Transplant; 2009 Jan 01; 24(1):73-84. PubMed ID: 18682491
    [Abstract] [Full Text] [Related]

  • 16. Improvement of endothelial function in a murine model of mild cholesterol-induced atherosclerosis by mineralocorticoid antagonism.
    Kratz MT, Schirmer SH, Baumhäkel M, Böhm M.
    Atherosclerosis; 2016 Aug 01; 251():291-298. PubMed ID: 27439215
    [Abstract] [Full Text] [Related]

  • 17. Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity.
    Hullin R, Métrich M, Sarre A, Basquin D, Maillard M, Regamey J, Martin D.
    Cardiovasc Res; 2018 Feb 01; 114(2):272-281. PubMed ID: 29016737
    [Abstract] [Full Text] [Related]

  • 18. More NO-no more ROS: combined selective mineralocorticoid receptor blockade and angiotensin-converting enzyme inhibition for vascular protection.
    Bauersachs J, Fraccarollo D.
    Hypertension; 2008 Mar 01; 51(3):624-5. PubMed ID: 18227402
    [No Abstract] [Full Text] [Related]

  • 19. Protective effects of ACE inhibitors on vascular endothelial dysfunction induced by exogenous advanced oxidation protein products in rats.
    Chen SX, Song T, Zhou SH, Liu YH, Wu SJ, Liu LY.
    Eur J Pharmacol; 2008 Apr 28; 584(2-3):368-75. PubMed ID: 18334254
    [Abstract] [Full Text] [Related]

  • 20. Eplerenone offsets cardiac and aortic adverse remodeling in spontaneously hypertensive rats.
    Burla AK, Neves MF, Oigman W, Mandarim-de-Lacerda CA.
    Int J Cardiol; 2007 Jan 02; 114(1):64-70. PubMed ID: 16650491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.